Articles related to Hematology

A quartet of current clinical trials involving first-in-class molecules and CRISPR gene editing show great promise. STELLAR investigates a fusion protein in PAH, CodeBreak 200 studies a first-in-class of KRAS inhibitor, EMERGENT-2 focuses on a new treatment for schizophrenia, and NCT04601051 studies a gene editing drug for one form of amyloidosis.

HBCLs, not-otherwise specified (NOS), are rare and heterogeneous; other than having germinal center B-cell phenotype, and in up to 45%, a single-hit MYC rearrangement, they have no unifying immunophenotypic or cytogenetic characteristics. This review discusses the current clinicopathologic concept of HGBL, NOS, and looks at potential future taxonomy enrichments based on emerging molecular diagnostics.

Over a 4-year period, 500 patients were distributed equally between the two regimens. Two-year OS, relapse rates, and non-relapse mortality were similar between the two regiments, indicating that the busulfan regimen is non-inferior to the traditional TBI regimen.

This review summarizes the clinical presentation, workup, staging, and recent advancements in the treatment of PCNSL. Although treatment advances include the use of BTK inhibitors and immunomodulators, relapse is common and 5-year survival is 40% or lower. Thus, accurate early diagnosis and initiation of treatment is time sensitive for optimal neurologic recovery and disease control.

Memorial Sloan Kettering oncologist Raajit Rampal presents a case report, discusses the rationale for the few treatment options available, and summarizes the 5-year follow-up data for the RESPONSE and RESPONSE 2 trials.

In this first part of a three-case series, a 65-year-old man received ruxolitinib for treatment and reported feeling much better after one month, and after two months of treatment, most of his symptoms had completely resolved and his blood cell counts were maintained under control.